Nebivolol Krka

Nebivolol, the active ingredient in Nebivolol Krka, is a Beta‑adrenergic receptor blocker presented as an oral tablet for oral use. It treats hypertension and heart failure in adult patients. GNH USA supplies Nebivolol Krka as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Nebivolol is a selective β1‑blocker used in cardiovascular conditions that require blood‑pressure reduction or improved cardiac function. - Hypertension: lowers systolic and diastolic blood pressure, reducing risk of stroke and myocardial infarction. - Heart failure: enhances cardiac output and alleviates symptoms of chronic heart failure. - Hypertension in chronic kidney disease: provides effective blood‑pressure control while preserving renal function.

Nebivolol may cause a range of adverse reactions, from mild to serious.

Common Side Effects: - Headache: mild to moderate intensity. - Dizziness or light‑headedness, especially on standing. - Fatigue or tiredness. - Nausea or abdominal discomfort. - Bradycardia: heart rate below 60 bpm. - Peripheral edema: mild swelling of ankles or feet.

Serious or Rare Side Effects: - Severe bradycardia or heart block requiring medical attention. - Symptomatic hypotension with fainting. - Bronchospasm or worsening asthma. - Acute heart failure decompensation. - Allergic reactions such as rash, angioedema, or anaphylaxis.

Before initiating Nebivolol, clinicians should consider several safety measures. - Blood pressure monitoring: ensure adequate control and avoid excessive drops. - Heart rate monitoring: watch for bradycardia, especially in patients on other rate‑lowering agents. - Respiratory caution: avoid in patients with severe asthma or chronic obstructive pulmonary disease. - Hepatic impairment: dose adjustment may be required in moderate to severe liver disease. - Discontinuation: taper gradually to prevent rebound hypertension or tachycardia. - Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Nebivolol can interact with several drug classes, altering its efficacy or safety profile.

Major Interactions (Avoid): - Other β‑blockers: additive bradycardia and hypotension. - Non‑dihydropyridine calcium‑channel blockers (verapamil, diltiazem): may cause severe bradycardia. - Strong CYP2D6 inhibitors (paroxetine, fluoxetine, quinidine): increase nebivolol plasma levels.

Moderate Interactions (Monitor Closely): - Diuretics: may potentiate hypotensive effect. - ACE inhibitors or ARBs: enhanced blood‑pressure lowering. - NSAIDs: may blunt antihypertensive response. - Antiarrhythmic agents (e.g., amiodarone): possible conduction disturbances.